Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Dyskinesia Due to Cerebral Palsy

NCT05206513 is registered in ClinicalTrials.gov with Neurocrine Biosciences as lead sponsor.

NCT NCT05206513
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05206513 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Dyskinesia Due to Cerebral Palsy
Lead sponsor
Neurocrine Biosciences
Phase
Phase 3
Overall status
Completed
Start date
April 15, 2022
Completion date
March 31, 2026
Enrollment
86 (actual)
Sites
38

Conditions

As the registry lists them; a condition with its own page is linked.

cerebral palsy, dyskinesia